Completed PHASE2 INTERVENTIONAL NCT00036023

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy

Sponsor: Amgen

Conditions Breast Neoplasms Chronic Lymphocytic Leukemia Lung Neoplasms Lymphoma Multiple Myeloma

Interventions darbepoetin alfa

Updated 5 times since 2017 Last updated: May 7, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00036023, this PHASE2 trial focuses on Breast Neoplasms and Chronic Lymphocytic Leukemia and remains completed. Sponsored by Amgen, it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.